Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement;Kosteneffectiviteit van nieuwe geneesmiddelen: van belang bij geneesmiddelenvergoeding, maar voor verbetering vatbaar.

Nederlands tijdschrift voor geneeskunde

Volumn 154, Issue 30, 2010, Pages

  Hoomans, Ties ^a   van der Roer, Nicole ^b   Severens, Johan L ^b   Delwel, Gepke O ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; HUMAN; NETHERLANDS; PHARMACOECONOMICS; PRACTICE GUIDELINE; REIMBURSEMENT; RETROSPECTIVE STUDY;

COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NETHERLANDS; RETROSPECTIVE STUDIES;

EID: 77956622173     PISSN: None     EISSN: 18768784     Source Type: Journal    
DOI: None     Document Type: Article

References (0)